If cyanorona-20 compound successfully passes the in vivo bioassays and preclinical/clinical trials with effectively significant results as anti-COVID-19 agent, a combination therapy (e.g., as an oral tablet or a nasal/oral prophylactic gel) with a second highly potent antiviral drug, such as remdesivir, will be a recommended possible choice for the COVID-19 treatment in the near future.
2
—
—
The sentences
Preceding studies and investigations have identified the viral RNA-dependent RNA polymerase (RdRp) as a very potential drug target in COVID-19 therapy due to its highly significant and pivotal role in SARS-CoV-2 replication and transcription (i.e., in the virus life cycle), and, furthermore, this enzyme has a strategic feature and advantage of being absolutely absent in the coronavirus-uninfected human cells (i.e., viral RdRp is a drug target of extremely selective toxicity for SARS-CoV-2 particles) [5] , [6] , [7] .